Engage Logo
    • Búsqueda Avanzada
  • Huésped
    • Acceder
    • Registrar
    • Modo día
BostonGene Corporation Cover Image
User Image
Arrastra la portada para recortarla
BostonGene Corporation Profile Picture
BostonGene Corporation
  • Cronología
  • Grupos
  • Me gusta
  • Amigos
  • Fotos
  • Videos
BostonGene Corporation profile picture
BostonGene Corporation
4 w - Traducciones

AI-Driven Disease Modeling Takes Focus at JSMO 2026

At JSMO 2026 in Yokohama, BostonGene shared how its disease modeling platform is helping advance precision oncology. By integrating diverse data sources, the approach supports better prediction of treatment outcomes, improved clinical trial design, and more informed therapeutic decisions. The model is increasingly being used by biopharma partners to strengthen research and patient care.

Read more on how AI is transforming oncology and drug development: https://bostongene.com/news-an....d-publications/news/

Me gusta
Comentario
Compartir
BostonGene Corporation profile picture
BostonGene Corporation
5 w - Traducciones

AI and Multiomics Powering Next-Gen Cancer Therapies

In a strategic collaboration, BostonGene and ImmunoGenesis are leveraging advanced AI and multiomic technologies to enhance the clinical development of IMGS-001. This innovative approach focuses on understanding tumor biology at a deeper level, helping identify which patients are most likely to benefit from treatment while improving the overall effectiveness of immunotherapy.

Learn how cutting-edge technologies are reshaping cancer treatment strategies: https://bostongene.com/news-an....d-publications/news/

Me gusta
Comentario
Compartir
BostonGene Corporation profile picture
BostonGene Corporation
6 w - Traducciones

BostonGene Showcases AI-Driven Breakthroughs at AACR 2026

BostonGene will present 13 abstracts at the AACR Annual Meeting 2026, highlighting its advanced AI-powered platform for tumor and immune biology. The company’s innovations focus on accelerating drug discovery, improving patient stratification, and reducing clinical development risks through multiomic data integration and cutting-edge analytics.

Explore the full announcement here: https://bostongene.com/news-an....d-publications/news/

BostonGene to Present 13 Abstracts at the American Association for Cancer Research Annual Meeting 2026 Showcasing AI-Platform for Drug Development | BostonGene
bostongene.com

BostonGene to Present 13 Abstracts at the American Association for Cancer Research Annual Meeting 2026 Showcasing AI-Platform for Drug Development | BostonGene

Me gusta
Comentario
Compartir
BostonGene Corporation profile picture
BostonGene Corporation
7 w - Traducciones

New Research Expands Treatment Possibilities in Advanced Cancers

Emerging research showcases how next-generation molecular profiling is helping uncover hidden treatment opportunities in patients with advanced cancers. By going beyond traditional testing methods, this approach enables the discovery of new therapeutic targets and broadens access to more personalized care options.

Read the full press release to learn more about these findings and their impact on the future of cancer treatment. https://bostongene.com/news-an....d-publications/news/

BostonGene RNA Transcriptome Profiling Reveals New ADC Targets in Advanced Solid Tumors | BostonGene
bostongene.com

BostonGene RNA Transcriptome Profiling Reveals New ADC Targets in Advanced Solid Tumors | BostonGene

Me gusta
Comentario
Compartir
BostonGene Corporation profile picture
BostonGene Corporation
9 w - Traducciones

AI is playing a big role in oncology research right now.

BostonGene is working with Ottimo Pharma to accelerate development of a new immuno oncology therapy using advanced analytics and multiomic data.

More details here:
https://bostongene.com/news-an....d-publications/news/

BostonGene Announces Collaboration with Ottimo Pharma to Optimize and Accelerate Development of First-in-Class PD-1/VEGFR2 Immuno-Oncology Therapy Using AI | BostonGene
bostongene.com

BostonGene Announces Collaboration with Ottimo Pharma to Optimize and Accelerate Development of First-in-Class PD-1/VEGFR2 Immuno-Oncology Therapy Using AI | BostonGene

Me gusta
Comentario
Compartir
 Cargar más publicaciones
    Información
  • 8 Mensajes

  • Hombre
  • 11/30/-1
  • Viviendo en United States
    Álbumes 
    0
    Amigos 
    0
    Me gusta 
    0
    Grupos 
    0

© 2026 Engage

Idioma
  • English
  • Arabic
  • Dutch
  • French
  • German
  • Italian
  • Portuguese
  • Russian
  • Spanish
  • Turkish

  • Pin
  • Contacto
  • Developers
  • Más información
    • Política
    • Condiciones
    • Solicitud de reembolso

No amigo

¿Estás seguro de que quieres unirte?

Reportar a este usuario

¡Importante!

¿Estás seguro de que deseas eliminar este miembro de tu familia?

Has pinchado BostonGene

¡El nuevo miembro se agregó a su lista de familia!

Recorta tu avatar

avatar

© 2026 Engage

  • Inicio
  • Pin
  • Contacto
  • Política
  • Condiciones
  • Solicitud de reembolso
  • Developers
Idioma
  • English
  • Arabic
  • Dutch
  • French
  • German
  • Italian
  • Portuguese
  • Russian
  • Spanish
  • Turkish

© 2026 Engage

  • Inicio
  • Pin
  • Contacto
  • Política
  • Condiciones
  • Solicitud de reembolso
  • Developers
Idioma
  • English
  • Arabic
  • Dutch
  • French
  • German
  • Italian
  • Portuguese
  • Russian
  • Spanish
  • Turkish

Comentario reportado con éxito

¡Se ha agregado el mensaje a tu línea de tiempo!

¡Has alcanzado el límite de 5000 amigos!

Error de tamaño de archivo: El archivo excede el límite permitido (954 MB) y no se puede cargar.

Se está procesando su video, le informaremos cuando esté listo para ver.

No se puede cargar un archivo: este tipo de archivo no es compatible.

Hemos detectado contenido para adultos en la imagen que subiste, por lo tanto, hemos rechazado tu proceso de carga.

Compartir publicación en un grupo

Compartir en una página

Compartir al usuario

Su publicación fue enviada, revisaremos su contenido pronto.

Para cargar imágenes, videos y archivos de audio, debe actualizar a miembro profesional. Para actualizar Pro

Editar oferta

0%